Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

TK and JPB Co-first; RK, DS, and AMZ are Co-senior authors. Introduction MDS with TP53 mutations ( TP53 MT) are associated with high-risk disease features and rapid progression to AML. Effective treatment for this aggressive subtype is still not available. As compared to monoallelic TP53 MT, biallel...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.1002-1002
Hauptverfasser:	Kewan, Tariq, Bewersdorf, Jan Philipp, Blaha, Ondrej, Stahl, Maximilian, Al Ali, Najla H, DeZern, Amy E., Sekeres, Mikkael A., Carraway, Hetty E., Desai, Pinkal, Griffiths, Elizabeth A., Stein, Eytan M., Brunner, Andrew M., Amaya, Maria L, Zeidner, Joshua F., Savona, Michael R., Stempel, Jessica M., Chandhok, Namrata Sonia, Cochran, Hunter, Ramaswamy, Rahul, Singh, Abhay, Roboz, Gail J., Rolles, Benjamin, Wang, Eunice S., Harris, Amyah C., Shallis, Rory M., Xie, Zhuoer, Padron, Eric, Maciejewski, Jaroslaw P., Della Porta, Matteo Giovanni, Komrokji, Rami S., Sallman, David A, Zeidan, Amer M.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!